Background
Hydatid disease is a parasitic infestation by a tapeworm of the genus Echinococcus. It is not endemic in the United States, but the change of immigration patterns and the improvement of transcontinental transportation over the past 4 decades have caused a rise in the profile of this previously unusual disease throughout North America. This has led to the necessity for physicians to be more aware of its clinical features, diagnosis, and management.
Pathophysiology
Human echinococcosis is a zoonotic infection caused by the tapeworm of the genus Echinococcus. Of the 4 known species of Echinococcus, 3 are of medical importance in humans. These are Echinococcus granulosus, causing cystic echinococcosis (CE); Echinococcus multilocularis, causing alveolar echinococcosis (AE); and Echinococcus vogeli. E granulosus is the most common of the three. E multilocularis is rare but is the most virulent, and E vogeli is the most rare.
Epidemiology
Frequency
United States
Despite the rise in occurrence, echinococcosis remains a very rare disease (< 1 case per 1 million inhabitants) in the continental United States. Northern Alaska has endemic areas of E granulosus, but the frequency of infection remains low (< 1 case per 100,000 inhabitants).
International
Echinococcosis is also unusual in northern Europe. The endemic areas are the Mediterranean countries, the Middle East, the southern part of South America, Iceland, Australia, New Zealand, and southern parts of Africa; the latter 5 are intensive endemic areas. The incidence of CE in endemic areas ranges from 1-220 cases per 100,000 inhabitants, while the incidence of AE ranges from 0.03-1.2 cases per 100,000 inhabitants, making it a much more rare form of echinococcosis. An epidemiological study of cyctic echinococcosis in Romania emphasized the need for improved preventive measures.[1] Infestation with E vogeli is the most rare form of echinococcosis and is reported mainly in the southern parts of South America.
Mortality/Morbidity
- Morbidity is usually secondary to free rupture of the echinococcal cyst (with or without anaphylaxis), infection of the cyst, or dysfunction of affected organs. Examples of dysfunction of affected organs are biliary obstruction, cirrhosis, bronchial obstruction, renal outflow obstruction, increased intracranial pressure secondary to mass, and hydrocephalus secondary to cerebrospinal fluid outflow obstruction.
- In CE, mortality is secondary to anaphylaxis, systemic complications of the cysts (eg, sepsis, cirrhosis, respiratory failure, or operative complications.
- In clinical cases of AE, the mortality rate is 50-60%. This figure reaches 100% for untreated or poorly treated AE. Sudden death has been reported with AE in asymptomatic patients (autopsy diagnosis).
Race
- Because of the restricted geographic distribution of the echinococcal worms, persons of certain races are affected more commonly than others; however, the parasite has the capability of infecting persons of all races equally.
Sex
- No sexual predilection is recognized.
Age
- The cysts grow slowly, and a cyst is rarely diagnosed during childhood or adolescence unless the brain is affected.
- CE is a disease of younger adults, with an average age at diagnosis of 30-40 years.
- AE is a disease of older adults, with an average age at diagnosis of older than 50 years.
Moldovan R, Neghina AM, Calma CL, Marincu I, Neghina R. Human cystic echinococcosis in two south-western and central-western Romanian counties: A 7-year epidemiological and clinical overview. Acta Trop. Jan 2012;121(1):26-9. [Medline].
Siracusano A, Delunardo F, Teggi A, Ortona E. Host-parasite relationship in cystic echinococcosis: an evolving story. Clin Dev Immunol. 2012;2012:639362. [Medline]. [Full Text].
Kapan S, Turhan AN, Kalayci MU, Alis H, Aygun E. Albendazole is not effective for primary treatment of hepatic hydatid cysts. J Gastrointest Surg. May 2008;12(5):867-71. [Medline].
Ochieng'-Mitula PJ, Burt MD. The effects of ivermectin on the hydatid cyst of Echinococcus granulosus after direct injection at laparotomy. J Parasitol. Feb 1996;82(1):155-7. [Medline].
Mamarajabov S, Kodera Y, Karimov S, Abdiev S, Sabirov B, Krotov N, et al. Surgical Alternatives for Hepatic Hydatid Disease. Hepatogastroenterology. Oct 12 2011;58(112):[Medline].
Elsebaie SB, El-Sebae MM, Esmat ME, Nasr MM, Kamel MM. Modified endocystectomy versus pericystectomy in echinococcus granulosus liver cysts: a randomized controlled study, and the role of specific anti-hydatid IgG4 in detection of early recurrence. J Egypt Soc Parasitol. Dec 2006;36(3):993-1006. [Medline].
Filippou D, Tselepis D, Filippou G, Papadopoulos V. Advances in liver echinococcosis: diagnosis and treatment. Clin Gastroenterol Hepatol. Feb 2007;5(2):152-9. [Medline].
Flisser A. Larval cestodes. In: Collier L, Balows A, Sussman M, eds. Topley and Wilson's Microbiology and Microbial Infections. Parasitology. Vol 5. 9th ed. New York, NY: Oxford University Press; 1998:539-60.
Gargouri M, Ben Amor N, Ben Chehida F, Hammou A, Gharbi HA, Ben Cheikh M, et al. Percutaneous treatment of hydatid cysts (Echinococcus granulosus). Cardiovasc Intervent Radiol. Jun-Jul 1990;13(3):169-73. [Medline].
Guidelines for treatment of cystic and alveolar echinococcosis in humans. WHO Informal Working Group on Echinococcosis. Bull World Health Organ. 1996;74(3):231-42. [Medline].
Heath DD. Immunology of echinococcus infections. In: Thompson R, Lymbery AJ, eds. Echinococcus and Hydatid Disease. Wallingford, Oxon: CAB International; 1995:183-200.
Kjossev KT, Losanoff JE. Hydatid cysts of the liver: TN(R)C classification. Int Surg. Oct-Dec 1998;83(4):311-3. [Medline].
Liu D, Lightowlers MW, Rickard MD. Evaluation of a monoclonal antibody-based competition ELISA for the diagnosis of human hydatidosis. Parasitology. Apr 1992;104 ( Pt 2):357-61. [Medline].
Liu YH, Wang XG, Chen YT, Yao YQ. Computer tomography of liver in alveolar echinococcosis treated with albendazole. Trans R Soc Trop Med Hyg. May-Jun 1993;87(3):319-21. [Medline].
Polo JR, Garcia-Sabrido JL. Sclerosing cholangitis associated with hydatid liver disease. Arch Surg. May 1989;124(5):637. [Medline].
Schröder R, Robotti G. New aspects in the management of alveolar echinococcosis involving the liver. World J Surg. Dec 1986;10(6):968-73. [Medline].
Tan A, Yakut M, Kaymakçioglu N, Ozerhan IH, Cetiner S, Akdeniz A. The results of surgical treatment and percutaneous drainage of hepatic hydatid disease. Int Surg. Oct-Dec 1998;83(4):314-6. [Medline].
Taylor BR, Langer B. Current surgical management of hepatic cyst disease. Adv Surg. 1997;31:127-48. [Medline].
Taylor DH, Morris DL. In vitro culture of Echinococcus multilocularis: protoscolicidal action of praziquantel and albendazole sulphoxide. Trans R Soc Trop Med Hyg. 1988;82(2):265-7. [Medline].
Todorov T, Mechkov G, Vutova K, Georgiev P, Lazarova I, Tonchev Z, et al. Factors influencing the response to chemotherapy in human cystic echinococcosis. Bull World Health Organ. 1992;70(3):347-58. [Medline].
von Sinner WN. New diagnostic signs in hydatid disease; radiography, ultrasound, CT and MRI correlated to pathology. Eur J Radiol. Mar-Apr 1991;12(2):150-9. [Medline].
Williams JF, Perez Esandi MV, Oriol R. Evaluation of purified lipoprotein antigens of Echinococcus granulosus in the immunodiagnosis of human infection. Am J Trop Med Hyg. Jul 1971;20(4):575-9. [Medline].

